Last reviewed · How we verify
Proxalutamide (GT0918)
Proxalutamide is an androgen receptor antagonist.
Proxalutamide is an androgen receptor antagonist. Used for Metastatic castration-resistant prostate cancer.
At a glance
| Generic name | Proxalutamide (GT0918) |
|---|---|
| Also known as | standard of care |
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Drug class | Androgen receptor antagonist |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of androgens, such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells. This can help slow or stop the growth of cancer cells.
Approved indications
- Metastatic castration-resistant prostate cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Muscle spasm
- Headache
Key clinical trials
- The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC (PHASE2)
- Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects (PHASE3)
- A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients (PHASE3)
- Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer (PHASE1)
- Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |